Fourth Quarter 2025 Earnings Non-GAAP Financial Data Disclosure This presentation, including documents incorporated herein by reference, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and un ...

Clene Inc. Conference Call Summary Company Overview - Clene Inc. is a clinical stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis) [1] Key Accomplishments and FDA Interactions - Clene has achieved an in-person meeting with the FDA this quarter, marking the fifth meeting in 14 months to discuss extensive biomarker and survival data [2] - The company presented significant biomarker analyses showing reductions in neurofilament and GFAP (glial fibrillary acidic protein), which are associated with longer survival in ALS patients [3][4] - Clene aims to file a new drug application (NDA) under the accelerated approval pathway, utilizing biomarker data as a surrogate endpoint due to missed primary endpoints in previous studies [5][6] Biomarker Data and Clinical Evidence - The company has demonstrated that reductions in neurofilament levels are quantitatively associated with improved survival, with a noted reduction of 9%-10% linked to lower mortality risk [8] - Clene is pursuing a three-pronged approach to validate the biomarker benefits, including proving substantial biomarker benefit, establishing an independent association with mortality, and demonstrating consistent clinical benefits [7][9] Future Plans and Timeline - The FDA meeting is scheduled for later this quarter, with the intent to file the NDA in the second quarter of 2024 if the FDA concurs with the data presented [11][12] - If accepted, commercialization could begin by early 2025, with aspirations to approve CNM-Au8 for ALS patients [13] Financing and Cash Runway - Clene raised approximately $6 million at a price of $6.50 per share through a tranche financing, extending its cash runway by an additional quarter [17] - Future tranches are planned, with potential raises of $7 million at $7 per share and $15 million at a $12.50 strike price upon approval [18] Industry Context and Need for New Treatments - There are over 30,000 ALS patients in the U.S., with a uniform mortality rate of 2-4 years without treatment, highlighting the urgent need for new drugs [19] - Clene is also working to reauthorize funding for ALS research at the Congressional level, emphasizing the critical need for advancements in treatment options [19] Conclusion - Clene Inc. is positioned to make significant strides in ALS treatment through its ongoing FDA interactions and biomarker research, with a clear plan for future drug application and funding strategies [20]

Summary of Global Crossing Airlines Group Conference Call Company Overview - **Company Name**: Global Crossing Airlines Group (OTCPK: JETM.F) - **Industry**: Charter Airline - **Established**: February 2020, certified as an airline in August 2021 - **Current Fleet**: 18 operating aircraft, plans for growth [4][10] Key Financial Metrics - **Valuation**: Trading at 2 times EBITDA, compared to peers sold for 6.9 times EBITDA [2] - **Market Size**: U.S. charter market estimated at $3.9 billion, cargo market at $5.8 billion, totaling approximately $9 billion revenue opportunity [10] - **2024 Revenue**: $223 million [10] - **Q3 Financials**: $58 million in revenue, $18.9 million EBITDA, 9,900 block hours flown [21] Business Model - **Charter Operations**: Operates on an ACMI (Aircraft Crew Maintenance Insurance) basis, which is more prevalent in Europe [7][12] - **Cost Structure**: No fixed schedule; revenue based on hourly rates for flights, with fuel and crew costs passed through to customers [12][13] - **Profitability Focus**: Aims for $300,000 to $400,000 operating income per aircraft per month [13] Growth Strategy - **Fleet Expansion**: Plans to grow from 20 aircraft, with current leasing strategy to avoid high lease rates [16][17] - **Base Locations**: Established bases in Miami, Alexandria, Louisiana, and Harlingen, Texas to enhance operational efficiency and competitiveness [18] - **Market Reach**: Flown to over 450 cities in 67 countries, with flexibility to adapt to customer needs [19][20] Competitive Landscape - **Market Position**: Largest charter operator in the U.S., capitalizing on competitors' failures due to high debt and service delivery issues [9][40] - **Risk Management**: Maintains a disciplined approach to fleet management and maintenance reserves to avoid operational pitfalls [41][42] Operational Insights - **Pilot Recruitment**: Offers unique benefits to pilots, including a Gateway Program allowing flexible living arrangements, which helps attract experienced captains [33][34] - **Maintenance Strategy**: Leases all aircraft, paying into maintenance reserves to ensure funds are available for heavy maintenance checks [41] Future Outlook - **Profitability Goals**: Focus on improving utilization and profitability through high-margin ACMI work, while navigating a weak cargo market [26] - **Investment Highlights**: Fastest-growing charter airline with a strong employee investment and belief in the company's future [28][30] Conclusion - **Overall Assessment**: The company believes its valuation does not reflect its growth potential and operational achievements, encouraging investors to consider the unit economics of adding aircraft to the fleet [43]

Financial Data and Key Metrics Changes - The fiscal year 2025 is viewed as a turning point for the company, marking a transformation from a lighting and lighting controls company to an industrial control company [12] - The lighting business continued to perform well despite market challenges, maintaining its position as the best-performing lighting company globally [12] Business Line Data and Key Metrics Changes - The acquisition of QSC has contributed to the growth of the AIS business, establishing it as a thriving second business that is positively impacting outcomes in various spaces [12] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to sustain strong performance in its lighting segment [12] Company Strategy and Development Direction - The company is focused on long-term growth, positioning itself as an innovator and disruptor in the industry, aiming to create stakeholder value and compound shareholder wealth [3] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the operational performance during the year and is optimistic about the foundation being built for fiscal 2026 and beyond [12] Other Important Information - The company successfully elected its board of directors and ratified the appointment of Ernst & Young as its independent registered public accounting firm for the fiscal year ending August 31, 2026 [10] Q&A Session Summary Question: What was the most important thing that happened this year? - Management highlighted the transformation of the company and the successful integration of QSC, along with the continued strong performance of the lighting business despite challenges [12]

Financial Data and Key Metrics Changes - The fiscal year 2025 is viewed as a turning point in the company's transformation from a lighting and lighting controls company to an industrial control company, indicating a strategic shift in focus [12] - The company reported that its lighting business continued to be the best-performing lighting company globally despite significant market challenges and policy upheaval [12] Business Line Data and Key Metrics Changes - The acquisition of QSC and the growth of the AIS business have resulted in a thriving second business that is changing outcomes in various spaces, showcasing diversification in revenue streams [12] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to maintain strong performance in its lighting segment, indicating resilience in a volatile market [12] Company Strategy and Development Direction - The company is positioned for long-term growth, emphasizing innovation, disruption, and stakeholder value creation as core components of its strategy [3] - The integration of QSC is highlighted as a successful move that enhances the company's operational capabilities [3] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the operational performance during the year and optimism about the foundation being built for fiscal 2026 and beyond [12] Other Important Information - The company successfully elected its board of directors and ratified the appointment of Ernst & Young as its independent registered public accounting firm for the fiscal year ending August 31, 2026 [10] Q&A Session Summary Question: What was the most important thing that happened this year? - The acquisition of QSC and the growth of the AIS business were identified as pivotal developments, marking a significant transformation for the company [12]

Summary of Simulations Plus Investor Day - January 21, 2026 Company Overview - **Company**: Simulations Plus (NasdaqGS:SLP) - **Industry**: Biopharmaceutical modeling and simulation - **Focus**: Drug development, commercialization, and scientific consulting Core Points and Arguments Industry Transformation - The biopharma industry is undergoing significant changes, including: - Adoption of AI - Shift towards cloud-native scientific computation - Move away from animal testing - Increased reliance on model-informed drug development [2][12][50] Company Vision and Mission - **Vision**: Improve quality of life through innovative solutions - **Mission**: Create value for clients by accelerating the discovery, development, and commercialization of pharmaceuticals through science-based software and consulting solutions [3][2] Unique Value Proposition - Simulations Plus differentiates itself through: - A combination of scientific excellence and technological innovation - A robust suite of software products including GastroPlus, MonolixSuite, ADMET Predictor, DILIsym, and Thileys [4][5] - The company is evolving from point solutions to an integrated cloud-enabled ecosystem [5] Market Opportunity - Total Addressable Market (TAM) is approximately $12.5 billion: - $4 billion in traditional biosimulation - $8.5 billion in clinical trial training and medical communications [6] Client Needs and Industry Pressures - Clients face pressures from: - Economic factors increasing the cost and complexity of drug development - Scientific complexity requiring advanced modeling techniques - Technological expectations for integrated digital infrastructure [10][11][12] Regulatory Environment - Regulatory agencies are pushing for broader use of model-informed drug development and non-animal methodologies, which aligns with Simulations Plus's offerings [12][56] Strategic Shift - The company is transitioning from a tool provider to an ecosystem partner, focusing on integrated workflows and AI-assisted solutions [14][28] Additional Important Insights Product Strategy and Roadmap - The company is building a unified AI-orchestrated ecosystem that connects various aspects of drug development [20][25] - The architecture includes: - Validated modeling engines - Composition layer for data standardization - Grounded intelligence layer with AI copilots - Orchestration layer for automating workflows [21][22][24] Services and Consulting - Simulations Plus's services complement its product offerings by providing scientific consulting that informs software enhancements and optimizes workflows [33][34] - The consulting teams help clients navigate complex drug development decisions, reducing uncertainty and costs [34][35] Case Studies - Case studies illustrate the effectiveness of Simulations Plus's approach in reducing development timelines and costs while improving clinical trial success rates [41][43] Future Growth and Revenue Opportunities - The acquisition of Pro-ficiency has doubled the TAM and is expected to contribute to future growth [54][55] - The company anticipates increased demand for simulation and modeling services driven by FDA's NAMs guidance [56][58] Pricing Evolution - The company is evolving its pricing strategy to reflect the added value of its integrated ecosystem, with new monetization opportunities expected as the ecosystem matures [29][30] Conclusion - Simulations Plus is well-positioned to lead in the evolving landscape of model-informed drug development, leveraging its scientific expertise, technological innovations, and strategic partnerships to create a cohesive platform that meets the industry's growing demands [53]

Financial Data and Key Metrics Changes - The company reported significant growth in fiscal year 2025, marking a turning point in its transformation from a lighting and lighting controls company to an industrial control company [13] - The acquisition of QSC and the growth of the AIS business contributed to a thriving second business, enhancing overall performance [13] Business Line Data and Key Metrics Changes - The lighting business continued to perform exceptionally well, maintaining its position as the best-performing lighting company globally despite market challenges [13] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to navigate these effectively, showcasing resilience in its operations [13] Company Strategy and Development Direction - The company is focused on long-term growth, positioning itself as an innovator and disruptor in the industry, aiming to create stakeholder value and compound shareholder wealth [3] - The integration of QSC is a key part of the company's strategy to enhance its industrial control capabilities [13] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the company's operations in fiscal year 2025 and is optimistic about the foundation being built for fiscal 2026 and beyond [13] Other Important Information - The company successfully ratified the appointment of Ernst & Young as its independent registered public accounting firm for fiscal year 2026 [11] Q&A Session Summary Question: What was the most important thing that happened this year? - Management highlighted the transformation into an industrial control company as a significant milestone, driven by the acquisition of QSC and the growth of the AIS business, while also noting the strong performance of the lighting business amidst challenges [13]

Ubisoft Strategic Update Call Summary Company Overview - **Company**: Ubisoft - **Industry**: Video Game Development Key Points Organizational and Operational Reset - Ubisoft announced a major organizational, operational, and portfolio reset aimed at reclaiming creative leadership and restoring sustainable growth and cash generation [2][5] - The reset is structured around three core pillars: 1. A new operating model with five specialized creative houses 2. A refocused portfolio with a revised three-year roadmap 3. Accelerated cost reduction initiatives to improve structural efficiency [2][4] New Operating Model - The new model will consist of five creative houses, each responsible for specific game genres and brands, enhancing accountability and decision-making speed [6][8] - Each creative house will have full financial ownership and accountability for its economic performance, focusing on long-term value creation [10][8] - The first creative house, Vantage Studios, aims to scale established franchises like Assassin's Creed and Far Cry into annual billion-dollar brands [9] - Other creative houses will focus on competitive shooters, live experiences, immersive fantasy worlds, and casual games [9] Portfolio Refocus - Ubisoft will discontinue six games that do not meet new quality expectations, including the Prince of Persia: The Sands of Time Remake and four unannounced titles [15] - Additional development time will be allocated to seven games to ensure quality benchmarks are met, delaying one unannounced title from fiscal year 2026 to 2027 [15] Cost Reduction Initiatives - The current cost reduction program aims for at least €100 million in fixed cost savings by March 2026, with a new target to reduce fixed costs by an additional €200 million over the next two years [17] - Total fixed cost reductions are expected to reach around €500 million by fiscal year 2023, bringing fixed costs to approximately €1.25 billion by March 2028 [17] Financial Guidance - Net bookings for fiscal year 2026 are expected to be around €1.5 billion, reflecting a €330 million gross margin reduction due to changes in the release pipeline [18] - Non-IFRS EBIT is projected at around €1 billion, influenced by transformation-related decisions leading to a one-off accelerated depreciation of approximately €650 million [18] - Free cash flow is anticipated to be between €400 million and €500 million, with non-IFRS net debt expected to be between €150 million and €250 million by year-end fiscal year 2026 [19] Market Position and Future Outlook - The reset is expected to have significant short-term financial impacts, particularly in fiscal years 2026 and 2027, but aims to position Ubisoft for sustainable growth and robust cash generation in the long term [20][21] - The company is committed to returning to positive free cash flow within the next three years, with a focus on exceptional content quality [27][24] Additional Insights - The competitive landscape in the AAA gaming market is becoming increasingly selective, with rising development costs and challenges in creating new brands [2][4] - Ubisoft's strategy includes a focus on partnerships, with no fundamental changes in approach, but rather a realignment with the new organizational structure [31] This summary encapsulates the key points from Ubisoft's strategic update call, highlighting the company's efforts to adapt to market challenges and position itself for future growth.

Summary of Northern Technologies International (NTIC) Conference Call Company Overview - **Company**: Northern Technologies International (NTIC) - **Industry**: Industrial packaging and corrosion solutions - **Key Products**: Zerust Excor (volatile corrosion inhibitors), Zerust Oil & Gas, Natur-Tec Bioplastics (compostable plastics) [1][2] Core Business Segments - **Zerust Industrial**: Traditional industrial packaging products, primarily serving automotive, construction, agriculture, and mining sectors [8][10] - **Zerust Oil & Gas**: Focus on protecting oil and gas infrastructure, including pipelines and storage tanks, with a recent $13 million contract in Brazil [11][12] - **Natur-Tec Bioplastics**: Development of certified compostable resins, capitalizing on global trends towards reducing single-use plastics [14][15] Growth Strategies - **Revenue Growth Target**: Aim for 15% top-line revenue growth while limiting operating expense growth to under 10% [6] - **Investment Focus**: Significant investments in oil and gas and Natur-Tec businesses expected to yield dividends in the next 1-5 years [7][27] - **Geographic Expansion**: Operations in 65 countries, with notable growth in China and India [2][5] Financial Performance - **Gross Margins**: Higher margins in oil and gas (60%+) compared to traditional industrial products; Natur-Tec margins improving due to lower raw material costs [18][29] - **Joint Ventures**: 15 international joint ventures contribute significantly to profitability, with NTIC receiving 10-11% of joint venture revenues as after-tax profit [20][38] Market Dynamics - **Competitive Advantage**: Global presence allows NTIC to provide comprehensive corrosion solutions, enhancing customer service and product differentiation [4][22] - **Market Trends**: Increasing demand for compostable plastics and corrosion solutions in oil and gas due to regulatory pressures and infrastructure investments [15][27] Operational Insights - **KPI Tracking**: Focus on gross margins and operating expenses to drive profitability; investments in sales and technical teams to enhance execution [34] - **Revenue Volatility**: Oil and gas contracts are project-based, leading to potential revenue fluctuations; however, new contracts may stabilize monthly revenues [30][31] Future Outlook - **Long-term Growth**: NTIC expects continued growth in oil and gas and Natur-Tec sectors, driven by market mandates and infrastructure investments [27][28] - **Strategic Planning**: Management emphasizes a compelling growth strategy across all business segments, aiming to leverage existing capabilities for future success [24][25] Additional Considerations - **Dividend Policy**: Recent reductions in dividends due to capital investments in growth areas, maintaining a conservative balance sheet [23] - **Market Diversification**: Efforts to reduce reliance on automotive markets by expanding into general industry and other sectors [26]

Financial Data and Key Metrics Changes - Q4 core FFO was $1.44 per share, finishing at the top end of guidance ranges [10] - Average occupancy was 95.3% for Q4 and 95% for the full year, with period-end occupancy at 95.8% [10] - Same-store NOI growth was 4.7% on a net effective basis and 5.7% on a cash basis, exceeding guidance [11] - Net effective rent change for the year was over 50%, with a quarterly change of 44% [10][11] Business Line Data and Key Metrics Changes - The company signed 57 million sq ft of leases in Q4, driving occupancy towards 96% [9] - Development platform, particularly build-to-suits, exceeded expectations, capturing significant market share [9] - The Data Center business saw a growing power pipeline, with expectations for solid starts in the upcoming year [9] Market Data and Key Metrics Changes - Q4 net absorption was 59 million sq ft in the U.S., leading to a decline in U.S. vacancy to 7.4% [14] - Many markets are experiencing a slowdown in rent decline, with some showing positive growth [14] - International markets, particularly in Latin America and Europe, are outperforming, with strong occupancy and rent growth [16] Company Strategy and Development Direction - The company focuses on three priorities: extending leadership as a best-in-class operator, capturing value creation opportunities in logistics and data centers, and enhancing shareholder returns through growth in assets under management [7][8] - The company aims to develop critical infrastructure in logistics and data centers, leveraging customer relationships and expertise [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational momentum and strategic initiatives in place for 2026, indicating a strong position for long-term growth [22] - The tone of customer conversations is increasingly positive, with e-commerce driving demand [15] - Management noted that while uncertainties exist, they are treated as planning assumptions rather than impediments [15] Other Important Information - The company sold approximately $900 million of value-maximized assets and acquired $625 million at attractive discounts [11] - The company achieved significant milestones in strategic capital, including the IPO of the China AMC Prologis Logistics REIT [17] Q&A Session Summary Question: Changes in strategic initiatives with new leadership - Management highlighted a focus on compounding the core logistics business while broadening the platform, with plans to grow strategic capital significantly [24][25] Question: Market rent growth expectations for 2026 - Management expects net absorption to approach 200 million sq ft in 2026, with vacancies declining to 7.1%-7.2% by year-end [33] Question: Data Center project details and guidance - Management indicated that 40% of the overall development starts guidance will be in Data Centers, with a mix of powered shell and turnkey projects [38] Question: Update on the 10 GW power outlook - Management remains confident in the 10 GW pipeline, emphasizing the significant opportunities available [43] Question: Capital deployment pipeline and ramp-up - Management noted that capital deployment decisions are made based on market conditions, with a significant number of opportunities available [56][57] Question: Same-store growth guidance breakdown - Management indicated that occupancy gains are expected across geographies, with a smaller contribution from mark-to-market as rent changes normalize [79]